Drugs / GRC-15300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01463397 | Mar 2012 → May 2013 | neuropathy, painful | Sanofi | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRC-15300 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707319 ↗ |
| Known as | SAR292833 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01463397 ↗ |
| Action | Inhibit | “Transient receptor potential cation channel subfamily V member 3 antagonist” CHEMBL3707319 ↗ |
| Route | Oral | “Route of administration: oral” NCT01463397 ↗ |
| Target | TRPV3 | “Transient receptor potential cation channel subfamily V member 3 antagonist” CHEMBL3707319 ↗ |